Werewolf Therapeutics, Inc.

A biopharmaceutical company focused on immuno-oncology, Werewolf Therapeutics develops therapeutically engineered molecules designed to activate the body's immune response against cancer and immune-mediated conditions. The company's approach centers on its PREDATOR platform, which creates conditionally activated molecules that target both adaptive and innate immunity pathways. This conditional activation mechanism aims to address limitations associated with conventional immunotherapies by restricting immune stimulation to diseased tissue.

The company's clinical-stage pipeline includes WTX-124, a conditionally activated Interleukin-2 molecule in development for advanced or metastatic solid tumors, and WTX-330, a conditionally activated Interleukin-12 molecule for advanced or metastatic solid tumors and lymphoma. Additional candidates in earlier development stages include molecules targeting interferon alpha, IL-10, IL-21, and IL-18 for oncology and inflammatory diseases. The company does not currently generate product revenue and operates as a pre-commercial development-stage entity.

Werewolf Therapeutics is incorporated in Delaware and headquartered in Watertown, Massachusetts, with 39 full-time employees. The company is publicly traded on Nasdaq. As of the most recent reporting period, the company maintains a minimal market capitalization and has not achieved profitability or product commercialization.